GlassScriptPhysician profile
Olga M Calof
NPI 1386667723
$4,302.38
in general payments reported to CMS, 2019-2025
13 companies · $1,613 in 2025
The $1,613 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $596 · 2020: $11.75 · 2021: $117 · 2022: $275 · 2023: $345 · 2024: $1,345 · 2025: $1,613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,229 · Education: $74.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,228.85 |
| Education | $74.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $1,963.09 | 2023-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $820.83 | 2019-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $400.41 | 2019-2025 | Wegovy |
| Lilly USA, LLC | $187.86 | 2019-2022 | |
| Horizon Therapeutics Plc | $173.69 | 2022-2023 | Tepezza |
| Sanofi-Aventis U.S. LLC | $161.29 | 2019-2024 | |
| Amgen INC. | $153.00 | 2025 | Tepezza |
| Amarin Pharma, INC. | $124.99 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $103.41 | 2021-2022 | |
| Insulet Corporation | $91.95 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.76 | 2019 | |
| Mannkind Corporation | $31.10 | 2024 | |
| Esperion Therapeutics, INC. | $22.00 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olga Calof listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.